Cargando…
PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy
BACKGROUND: The rapid development of programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors has generated an urgent need for biomarkers assisting the selection of patients eligible for therapy. The use of PD-L1 immunohistochemistry, which has been suggested as a predictive biomarker,...
Autores principales: | Gevensleben, Heidrun, Holmes, Emily Eva, Goltz, Diane, Dietrich, Jörn, Sailer, Verena, Ellinger, Jörg, Dietrich, Dimo, Kristiansen, Glen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346762/ https://www.ncbi.nlm.nih.gov/pubmed/27835597 http://dx.doi.org/10.18632/oncotarget.13161 |
Ejemplares similares
-
PITX3 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients after radical prostatectomy
por: Holmes, Emily Eva, et al.
Publicado: (2016) -
CXCL12 promoter methylation and PD-L1 expression as prognostic biomarkers in prostate cancer patients
por: Goltz, Diane, et al.
Publicado: (2016) -
Clinical performance validation of PITX2 DNA methylation as prognostic biomarker in patients with head and neck squamous cell carcinoma
por: Sailer, Verena, et al.
Publicado: (2017) -
PITX3 DNA methylation is an independent predictor of overall survival in patients with head and neck squamous cell carcinoma
por: Sailer, Verena, et al.
Publicado: (2017) -
PD-1 (PDCD1) Promoter Methylation Is a Prognostic Factor in Patients With Diffuse Lower-Grade Gliomas Harboring Isocitrate Dehydrogenase (IDH) Mutations
por: Röver, Lea Kristin, et al.
Publicado: (2018)